🚀 VC round data is live in beta, check it out!
Largest Health & Beauty Public Companies
Benchmark revenue and EBITDA valuation multiples for public comps like
AbbVie, Procter & Gamble, L'Oreal, Novo Nordisk and Unilever.
 | $234 | +12% | $414B | $476B | 7.6x | 18.1x | ||
| $164 | -4% | $380B | $407B | 4.7x | 17.1x | ||
 | $439 | +11% | $234B | $237B | 4.5x | 19.0x | ||
 | $37 | -45% | $166B | $182B | 3.8x | 7.9x | ||
 | $71 | +3% | $155B | $182B | 3.0x | 13.5x | ||
| $253 | -17% | $117B | $130B | 3.8x | 15.8x | ||
| $97 | +4% | $78B | $85B | 4.1x | 17.0x | ||
 | $26 | +5% | $60B | $60B | 8.5x | 36.8x | ||
| $85 | +17% | $55B | $66B | 3.6x | 11.9x | ||
| $5 | +2% | $48B | $57B | 3.8x | 14.8x | ||
 | $47 | +84% | $46B | $84B | 1.6x | 7.5x | ||
 | $188 | +58% | $44B | $46B | 8.6x | 36.1x | ||
| $89 | +11% | $37B | $38B | 1.6x | 8.9x | ||
| $100 | +52% | $36B | $43B | 2.9x | 19.1x | ||
| $19 | -21% | $36B | $44B | 2.9x | 12.6x | ||
| $677 | +85% | $30B | $32B | 2.6x | 17.5x | ||
| $121 | -12% | $27B | $24B | 2.1x | 12.3x | ||
| $104 | -6% | $25B | $26B | 4.3x | 18.5x | ||
 | $30 | -3% | $20B | $23B | 1.5x | 8.4x | ||
 | $42 | +4% | $19B | $19B | 1.7x | 11.4x | ||
| $82 | -3% | $16B | $18B | 4.4x | 13.9x | ||
 | $8 | 0% | $15B | $13B | 2.1x | 14.4x | ||
| $13 | +7% | $14B | $14B | 8.3x | 40.2x | ||
| $7 | -13% | $11B | $9B | 1.5x | 8.8x | ||
| $8 | +20% | $11B | $11B | 7.4x | 42.6x | ||
| $25 | -6% | $10B | $11B | 7.0x | 28.2x | ||
 | $18 | -1% | $10B | $11B | 1.8x | 8.6x | ||
| $6 | +3% | $10B | $10B | 6.7x | 35.8x | ||
| $20 | +15% | $8B | $9B | 1.5x | 13.0x | ||
 | $182 | +277% | $7B | $7B | 5.9x | 22.9x | ||
| $25 | -5% | $7B | $7B | 10.1x | 32.2x | ||
| $96 | +54% | $7B | $6B | 2.1x | 15.0x | ||
 | $18 | +25% | $6B | $11B | 2.2x | 12.2x | ||
 | $0 | +78% | $5B | $5B | 2.4x | 15.1x | ||
| $29 | -8% | $5B | $5B | 11.0x | 32.2x | ||
| $82 | +30% | $5B | $6B | 3.5x | 17.1x | ||
| $16 | -9% | $5B | $4B | 1.3x | 8.2x | ||
| $4 | -53% | $4B | $3B | 3.8x | 9.6x | ||
| $51 | +6% | $4B | $5B | 1.6x | 6.8x | ||
| $4 | +33% | $4B | $4B | 1.3x | 8.2x | ||
| $11 | -12% | $4B | $4B | 2.2x | 12.2x | ||
| $124 | -16% | $4B | $4B | 8.2x | 31.3x | ||
| $15 | +10% | $3B | $3B | 1.6x | 9.5x | ||
| $12 | +6% | $3B | $3B | 1.0x | 7.6x | ||
| $69 | -20% | $3B | $4B | 3.9x | 11.7x | ||
| $8 | +33% | $3B | $3B | 2.3x | 14.9x | ||
| $94 | -17% | $3B | $3B | 2.0x | 9.9x | ||
| $91 | +5% | $3B | $3B | 8.6x | 30.5x | ||
| $7 | +8% | $3B | $2B | 3.0x | 22.3x | ||
 | $19 | +14% | $3B | $3B | 1.3x | 8.9x | ||
| $169 | -14% | $3B | $2B | 0.5x | 7.5x | ||
| $61 | -15% | $2B | $3B | 1.0x | 5.5x | ||
| $1 | +15% | $2B | $2B | 5.5x | 16.0x | ||
| $5 | 0% | $2B | $2B | 3.6x | 17.4x | ||
| $27 | -34% | $2B | $2B | 2.3x | 10.5x | ||
 | $2 | -- | $2B | $3B | 0.7x | 6.0x | ||
| $5 | -17% | $2B | $2B | 5.1x | 19.7x | ||
| $2 | -55% | $2B | $5B | 0.9x | 5.6x | ||
| $0 | -17% | $2B | $2B | — | — | ||
 | $3 | +26% | $2B | $3B | 0.8x | 5.4x | ||
| $22 | +73% | $2B | $1B | — | — | ||
| $4 | -5% | $2B | $2B | 6.2x | 17.6x | ||
| $30 | +81% | $2B | $2B | 2.2x | 11.4x | ||
| $3 | +12% | $2B | $2B | 1.7x | 12.0x | ||
| $6 | +26% | $2B | $2B | 2.4x | 11.8x | ||
| $12 | -56% | $2B | $5B | 1.1x | 6.9x | ||
| $136 | +22% | $2B | $2B | 1.2x | 10.4x | ||
 | $14 | -8% | $1B | $1B | 1.2x | 7.9x | ||
| $50 | +18% | $1B | $2B | 0.9x | 7.4x | ||
| $27 | +20% | $1B | $1B | 2.3x | 11.7x | ||
| $3 | +32% | $1B | $1B | 4.1x | 46.2x | ||
| $2 | +28% | $1B | $1B | 2.7x | 12.3x | ||
 | $17 | +12% | $1B | $1B | 1.6x | 10.7x | ||
 | $1 | +33% | $1B | $953M | 2.1x | 8.9x | ||
| $22 | -29% | $1B | $2B | 1.1x | 8.5x | ||
| $7 | +50% | $1B | $1B | 1.7x | 7.0x | ||
| $56 | +1% | $935M | $903M | 6.2x | 19.9x | ||
| $2 | +133% | $845M | $893M | 0.8x | 7.4x | ||
| $13 | -70% | $747M | $941M | 1.2x | 6.6x | ||
| $0 | +12% | $736M | $504M | — | — | ||
| $68 | +120% | $726M | $794M | 1.8x | 10.9x | ||
 | $474 | -8% | $668M | $717M | — | — | ||
 | $12 | +2% | $665M | $646M | — | — | ||
 | $17 | +53% | $650M | $931M | 1.1x | 5.9x | ||
| $1 | +4% | $456M | $587M | 0.8x | 6.4x | ||
 | $5 | -48% | $408M | $1B | 0.5x | 4.9x | ||
| $17 | -68% | $396M | $1B | 0.7x | 7.1x | ||
| $8 | +11% | $389M | $456M | 0.3x | — | ||
| $3 | -40% | $313M | $257M | 0.7x | 11.8x | ||
| $4 | -64% | $278M | $389M | 1.3x | (20.1x) | ||
| $3 | -41% | $261M | $252M | 1.8x | 8.3x | ||
| $7 | +44% | $249M | $321M | — | — | ||
| $1 | +59% | $247M | $279M | — | — | ||
| $4 | -19% | $240M | $153M | 0.8x | 5.3x | ||
| $22 | -- | $218M | $517M | 0.8x | 3.7x | ||
| $2 | -43% | $211M | $395M | 1.4x | 19.9x | ||
| $1 | +25% | $179M | $211M | 0.5x | 6.7x | ||
| $45 | +13% | $170M | $201M | 1.0x | — | ||
| $9 | -27% | $161M | $70M | — | — | ||
| $17 | -16% | $158M | $125M | 0.5x | 5.5x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of last 12 months. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.